As inhibition of FasL expression in colon cancer cells significantly retards tumour formation in mice (Ryan et al, 2005), these findings suggest that targeting the EP1 receptor may help to prevent or treat colon cancer, in part through preventing FasL upregulation in tumour cells. The gene discussed is FASLG; the disease is malignant colon neoplasm.